Modern Chinese Medicine Group Reports 15.4% Revenue Decline, Swings to RMB2.5 Million Profit, EPS Improves to RMB0.41 Cents

Reuters
08/29
Modern Chinese Medicine Group Reports 15.4% Revenue Decline, Swings to RMB2.5 Million Profit, EPS Improves to RMB0.41 Cents

Modern Chinese Medicine Group Co. Ltd. has released its interim results for the six months ended 30 June 2025. The company reported a revenue decrease of approximately 15.4%, dropping from RMB76.6 million in the previous period to RMB64.8 million in the current period. Despite the decline in revenue, the company recorded a shift from a loss of RMB6.9 million in the previous period to earnings of RMB2.5 million for the current period. This improvement in profitability is also reflected in the earnings per share, which turned from a loss of RMB1.14 cents to earnings of RMB0.41 cents. The gross profit also saw a decrease of approximately 25.3%, falling from RMB21.7 million to RMB16.2 million. The company managed to improve its profit before tax, reporting a figure of RMB3.43 million compared to a loss of RMB4.33 million in the previous period. Additionally, other income, gains, and losses netted RMB1.41 million, a significant improvement from a loss of RMB8.41 million in the previous period. No specific updates regarding the company's business operations or future outlook were provided in the interim results announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modern Chinese Medicine Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10